Stanislav Lazarev1, Heather McGee1, Erin Moshier2, Meng Ru2, Elizabeth G Demicco3, Vishal Gupta4. 1. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. 2. Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York. 3. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York. 4. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Vishal.Gupta@mountsinai.org.
Abstract
PURPOSE: The timing of perioperative radiation therapy (RT) in the treatment of soft tissue sarcoma (STS) varies among institutions. This study examines patterns of care, trends in utilization, and survival with preoperative versus postoperative RT for primary STS. METHODS AND MATERIALS: Using the National Cancer Data Base, we identified patients with stage I-III STS who underwent definitive surgery with either preoperative or postoperative RT between 2004 and 2012. Univariate, bivariate, and multivariate analyses were performed to identify factors predicting receipt of preoperative versus postoperative RT. Overall survival (OS) was analyzed using the log-rank test, Kaplan-Meier method, and Cox proportional-hazards model. RESULTS: This study included 9604 patients: 7246 (75.4%) received postoperative and 2358 (24.6%)-preoperative RT. Chemotherapy was administered to 27.0% patients in the preoperative and 13.0% in the postoperative cohort. Use of preoperative RT increased over time, from 16.8% in 2004 to 29.7% in 2012. Multivariate analysis revealed that preoperative RT utilization increased with the following factors: higher educational attainment, treatment at an academic facility, further distance from facility (>60 miles), receipt of chemotherapy, tumor originating in lower extremities, >10 cm tumors, and myxoid liposarcoma. OS analysis revealed no difference between the 2 treatment cohorts. CONCLUSIONS: Postoperative RT is used much more commonly than preoperative RT in localized STS; however, preoperative RT use has increased in recent years. Multiple demographic and clinicopathologic factors were predictive of preoperative RT use. Consistent with randomized phase 3 data, there was no difference in OS.
PURPOSE: The timing of perioperative radiation therapy (RT) in the treatment of soft tissue sarcoma (STS) varies among institutions. This study examines patterns of care, trends in utilization, and survival with preoperative versus postoperative RT for primary STS. METHODS AND MATERIALS: Using the National Cancer Data Base, we identified patients with stage I-III STS who underwent definitive surgery with either preoperative or postoperative RT between 2004 and 2012. Univariate, bivariate, and multivariate analyses were performed to identify factors predicting receipt of preoperative versus postoperative RT. Overall survival (OS) was analyzed using the log-rank test, Kaplan-Meier method, and Cox proportional-hazards model. RESULTS: This study included 9604 patients: 7246 (75.4%) received postoperative and 2358 (24.6%)-preoperative RT. Chemotherapy was administered to 27.0% patients in the preoperative and 13.0% in the postoperative cohort. Use of preoperative RT increased over time, from 16.8% in 2004 to 29.7% in 2012. Multivariate analysis revealed that preoperative RT utilization increased with the following factors: higher educational attainment, treatment at an academic facility, further distance from facility (>60 miles), receipt of chemotherapy, tumor originating in lower extremities, >10 cm tumors, and myxoid liposarcoma. OS analysis revealed no difference between the 2 treatment cohorts. CONCLUSIONS: Postoperative RT is used much more commonly than preoperative RT in localized STS; however, preoperative RT use has increased in recent years. Multiple demographic and clinicopathologic factors were predictive of preoperative RT use. Consistent with randomized phase 3 data, there was no difference in OS.
Authors: Geert J M G van der Heijden; A Rogier T Donders; Theo Stijnen; Karel G M Moons Journal: J Clin Epidemiol Date: 2006-07-11 Impact factor: 6.437
Authors: S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Sagus Sampath; Timothy E Schultheiss; Ying J Hitchcock; R Lor Randall; Dennis C Shrieve; Jeffrey Y C Wong Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-01 Impact factor: 7.038
Authors: Gunar K Zagars; Matthew T Ballo; Peter W T Pisters; Raphael E Pollock; Shreyaskumar R Patel; Robert S Benjamin Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Brian O'Sullivan; Aileen M Davis; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Rita Kandel; Karen Goddard; Anna Sadura; Joseph Pater; Benny Zee Journal: Lancet Date: 2002-06-29 Impact factor: 79.321
Authors: Karen L Sherman; Jeffrey D Wayne; Jeanette Chung; Mark Agulnik; Samer Attar; John P Hayes; William B Laskin; Terrance D Peabody; David J Bentrem; Raphael E Pollock; Karl Y Bilimoria Journal: J Surg Oncol Date: 2013-12-20 Impact factor: 3.454
Authors: H G Lyu; L V Saadat; M M Bertagnolli; J Wang; E H Baldini; M Stopfkuchen-Evans; R Bleday; C P Raut Journal: Br J Surg Date: 2020-07-03 Impact factor: 6.939
Authors: Jules Lansu; Winan J Van Houdt; Michael Schaapveld; Iris Walraven; Michiel A J Van de Sande; Vincent K Y Ho; Rick L Haas Journal: Sarcoma Date: 2020-09-22
Authors: David M Routman; Elizabeth Yan; Sujay Vora; Jennifer Peterson; Anita Mahajan; Kaisorn L Chaichana; Nadia Laack; Paul D Brown; Ian F Parney; Terry C Burns; Daniel M Trifiletti Journal: Front Neurol Date: 2018-11-13 Impact factor: 4.003
Authors: Siyer Roohani; Felix Ehret; Marta Kobus; Anne Flörcken; Sven Märdian; Jana Käthe Striefler; Daniel Rau; Robert Öllinger; Armin Jarosch; Volker Budach; David Kaul Journal: Radiat Oncol Date: 2022-09-14 Impact factor: 4.309
Authors: Marta Kobus; Siyer Roohani; Felix Ehret; Anne Flörcken; Jana Käthe Striefler; Franziska Brandes; Sven Märdian; Daniel Rau; Silvan Wittenberg; Robert Öllinger; David Kaul Journal: Radiat Oncol Date: 2022-08-08 Impact factor: 4.309